Table 6.

Relationship between the pretreatment PGR and FPR and clinicopathological factors

	PGR				FPR
	Low	High	χ 2	P‐value	Low	High	χ 2	P‐value
Age (y)
>60	18	17	5.260	0.022	15	20	1.701	0.192
≤60	9	27			21	15
Performance status
2	1	3	–	1.000*	3	1	–	0.614*
0/1	26	41			33	34
Body mass index (kg/m2)
<18.5 or >25	5	14	1.510	0.219	13	6	3.258	0.071
≥18.5 to <25	22	30			23	29
Location of primary tumor
Left‐sided colon	19	33	0.183	0.669	27	25	0.115	0.734
Right‐sided colon	8	11			9	10
Histological type
Poorly/mucinous	12	12	2.205	0.138	11	13	0.344	0.557
Well/moderately	15	32			25	22
Unresectable tumor
Synchronous	23	30	2.556	0.110	24	29	2.458	0.117
Metachronous	4	14			12	6
Number of organs affected by metastasis
More than one organ	15	15	3.159	0.075	11	19	4.096	0.043
One organ	12	29			25	16
RAS/BRAF gene
Mutations	8	14	0.045	0.833	10	12	0.325	0.569
Wild type	11	17			15	13
CEA (ng/mL)
>5	24	32	2.623	0.105	25	31	3.896	0.048
≤5	3	12			11	4
CA19‐9 (U/mL)
>37	23	17	14.739	<0.001	14	26	9.039	0.003
≤37	4	27			22	9
Hemoglobin (g/L)
<115	16	8	12.617	<0.001	5	19	12.942	<0.001
≥115	11	36			31	16
Targeted therapy
No	15	20	0.683	0.409	16	19	0.688	0.407
Yes	12	24			20	16

^*Fisher χ ².